Marshall Wace
VTVT icon

Marshall Wace’s vTv Therapeutics VTVT Stock Holding History

Marshall Wace’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
39,560
+26,171
+195% +$908K ﹤0.01% 2011
2026
Q1 		$531K Buy
+13,389
New +$486K ﹤0.01% 2421
2021
Q4 		– Sell
-585
Closed -$36K – 4313
2021
Q3 		$36K Sell
585
-6,221
-91% -$469K ﹤0.01% 2944
2021
Q2 		$621K Buy
6,806
+2,381
+54% +$241K ﹤0.01% 2039
2021
Q1 		$499K Buy
+4,425
New +$435K ﹤0.01% 1943

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace's VTVT Position: Q2 2026 in Review

Marshall Wace increased its vTv Therapeutics (VTVT) stake by 195% in Q2 2026, buying an estimated $908K and bringing the position to 39,560 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Marshall Wace first reported a position in VTVT in Q1 2021 and has held it in 5 quarters since. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Marshall Wace held 39,560 shares of vTv Therapeutics worth $1.49M as of Q2 2026.
  • Marshall Wace bought 26,171 vTv Therapeutics shares in Q2 2026, an estimated $908K.
  • vTv Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2011 holding.
  • Marshall Wace first reported a position in vTv Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.